Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-184-7 | CAS number: 79-19-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Acute toxicity: Oral route
The acute oral median lethal dose (LD50) for the test compound thiosemicarbazide is found to be 94.0 mg/kg in deer mice.
Acute toxicity: Inhalation
In accordance with column 2 of Annex VIII of the REACH regulation, inhalation is not the most likely route of exposure considering the vapour pressure and particle size of the chemical thiosemicarbazide and hence this end point was considered for waiver. Thus acute toxicity by the inhaltion route is unlikely.
Acute toxicity: Dermal route
The acute dermal median lethal dose (LD50) for the ) for the test compound thiosemicarbazide is found to be 2200 mg/kg with 95% confidence limit of 1240-2760 mg/Kg.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Data is from publication
- Qualifier:
- according to guideline
- Guideline:
- other: as below
- Principles of method if other than guideline:
- An acute oral toxicity study was conducted to evaluate toxicity of Thiosemicarbazide in deer mice
- GLP compliance:
- not specified
- Test type:
- other: No data available
- Limit test:
- yes
- Species:
- mouse
- Strain:
- other: Peromyscus maniculatus
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Wild-trapped house and deer mice
or domestically bred house mice were used
- Age at study initiation: No data available
- Weight at study initiation: 20 g
- Fasting period before study: No data available
- Housing: No data available
- Diet (e.g. ad libitum): Wheat seeds
- Water (e.g. ad libitum): No data available
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): No data available
- Humidity (%): No data available
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): No data available
IN-LIFE DATES: From: To: No data available - Route of administration:
- oral: gavage
- Vehicle:
- other: Water, corn oil, or 1.0% carbopol
- Details on oral exposure:
- No detailed data about vehicle available
- Doses:
- Dosing details not available
- No. of animals per sex per dose:
- 6 animals
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 3 days
- Frequency of observations and weighing: No data available
- Necropsy of survivors performed: No data available
- Other examinations performed: Mortality was observed - Statistics:
- Method of Thompson (1948) and Thompson and Weil (1952)
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 94 mg/kg bw
- Based on:
- test mat.
- Interpretation of results:
- Toxicity Category III
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral median lethal dose (LD50) for the test compound thiosemicarbazide is found to be 94.0 mg/kg in deer mice.
- Executive summary:
An acute oral toxicity study was conducted to evaluate toxicity ofThiosemicarbazidein deer mice.
The chemical was administered by gavage using water, corn oil, or 1.0% carbopol as carriers, followed by 3-days of observations for mortality.
The acute oral median lethal dose (LD50) for the test compound thiosemicarbazide is found to be 94.0 mg/kg.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 94 mg/kg bw
- Quality of whole database:
- Data is from peer reviewed publication
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- exposure considerations
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Data is from NTRL report
- Qualifier:
- according to guideline
- Guideline:
- other: as below
- Principles of method if other than guideline:
- Acute dermal toxicity study of Thiosemicarbazide was carried out in New Zealand White rabbit.
- GLP compliance:
- not specified
- Test type:
- other: No data
- Limit test:
- no
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Marland Breeding Farms, Inc., Hewitt. N.J
- Age at study initiation: No data available
- Weight at study initiation: 2.5-3.5 kg
- Fasting period before study: No data available
- Housing: No data available
- Diet (e.g. ad libitum): No data available
- Water (e.g. ad libitum): No data available
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): No data available
- Humidity (%): No data available
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): No data available
IN-LIFE DATES: From: To: No data available - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: trunk
- % coverage: 10% of the body surface area
- Type of wrap if used: The test material was held in contact with the skin by an 8-ply gauze wrapping which was moistened with physiological saline. At the 1.4 g/kg dose level, 5.0 ml of saline was used per animal. At the 2.0, 2.8, and 4.0 g/kg dose levels. 10.0 ml of saline was used per animal.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): The exposed area was wiped free of excess test material.
- Time after start of exposure:24 hrs
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 1.4, 2.0, 2.8, 4 g/kg (1400, 2000, 2800, 4000mg/kg)
- Concentration (if solution): Not applicable
- Constant volume or concentration used: yes
- For solids, paste formed: no
Additional information:
The hair of each rabbit was clipped from the trunk so as to expose at least 10% of the body surface area. The skin of half the animals (4 males, 4
females) was abraded longitudinally every 2 or 3 centimeters so as to penetrate the stratum corneum but not so deep as to disturb the derma or produce bleeding. - Duration of exposure:
- 24 hours
- Doses:
- 1.4, 2.0, 2.8, 4 g/kg (1400, 2000, 2800, 4000mg/kg)
- No. of animals per sex per dose:
- Total 16
1400 mg/Kg: 3 + 1 (additional 1 animal removed during the Day 2 of study due to broken back)
2000 mg/Kg: 4
2800 mg/Kg: 3 + 1 (additional 1 animal removed during the Day 2 of study due to broken back)
4000 mg/Kg: 4 - Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: mortality and overt signs of effect were made a 0-2 and 4-6 hours and daily thereafter for fourteen days.
Body weights were recorded initially on Day 7 and terminally (Day 14).
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight, and histopathology. - Statistics:
- No data available
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 200 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 1 240 - 2 760
- Mortality:
- Mortality observed at all dose group
- Clinical signs:
- At the twenty-four hour dermal observation none or very slight erythema accompanied by none or very slight edema was noted in all surviving animals.
Commonly Observed Signs: Nasal Discharge, Piloerection, Motor Activity Decrease, Motor Activity Increase, Ocular Discharge. - Body weight:
- The majority of the surviving animals at all dose levels exhibited a net body weight gain. At the 2000, 2800 and 4000 mg/kg dose levels, one animal per dose level showed a net loss of body weight.
- Gross pathology:
- Gross abnormalities were observed in lungs, eyes, kidney
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute dermal median lethal dose (LD50) for the ) for the test compound thiosemicarbazide is found to be 2200 mg/kg with 95% confidence limit of 1240-2760 mg/Kg.
- Executive summary:
Acute dermal toxicity study of Thiosemicarbazide was carried out in New Zealand White rabbit. The rats were treated at a dose level of 1400, 2000, 2800, 4000 mg/kg.
The hair of each rabbit was clipped from the trunk so as to expose at least 10% of the body surface area. The test material was held in contact with the skin by an 8-ply gauze wrapping which was moistened with physiological saline.
On the basis of observation made, the acute dermal median lethal dose (LD50) for thefor the test compound thiosemicarbazide is found to be 2200 mg/kg with 95% confidence limit of 1240-2760 mg/Kg.
Reference
Mortality:
Dose level (mg/kg) |
Mortality |
1400 |
3/3 |
2000 |
2/4 |
2800 |
2/3 |
4000 |
2/4 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 200 mg/kg bw
- Quality of whole database:
- Data is from NTRL report
Additional information
Acute toxicity: Oral route
The acute oral median lethal dose (LD50) for the test compound thiosemicarbazide is found to be 94.0 mg/kg in deer mice.
The supporting studies also indicate the test substance to be toxic by oral route.
Acute toxicity: Inhalation
In accordance with column 2 of Annex VIII of the REACH regulation, inhalation is not the most likely route of exposure considering the vapour pressure and particle size of the chemical thiosemicarbazide and hence this end point was considered for waiver. Thus acute toxicity by the inhaltion route is unlikely.
Acute toxicity: Dermal route
The acute dermal median lethal dose (LD50) for the ) for the test compound thiosemicarbazide is found to be 2200 mg/kg with 95% confidence limit of 1240-2760 mg/kg.
Justification for selection of acute toxicity – oral endpoint
The acute oral median lethal dose (LD50) for the test compound thiosemicarbazide is found to be 94.0 mg/kg in deer mice.
Justification for selection of acute toxicity – inhalation endpoint
In accordance with column 2 of Annex VIII of the REACH regulation, inhalation is not the most likely route of exposure considering the vapour pressure and particle size of the chemical thiosemicarbazide and hence this end point was considered for waiver. Thus acute toxicity by the inhaltion route is unlikely.
Justification for selection of acute toxicity – dermal endpoint
The acute dermal median lethal dose (LD50) for the ) for the test compound thiosemicarbazide is found to be 2200 mg/kg with 95% confidence limit of 1240-2760 mg/Kg.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.